NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Trump Says Anthropic No Longer Seen as National Security Threat 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation in two investor conferences during the month of February.
The 18th Annual BIO CEO & Investor Conference
On Tuesday, February 9, 2016, Christopher J. Molineaux, Ph.D., Senior Vice President of Development, will present a corporate update at 2:30 pm EST. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City.
Leerink Global Healthcare Conference
On Wednesday, February 10, 2016, Dr. Molineaux will participate in a fireside chat to discuss recent corporate developments at the Leerink Global Healthcare Conference being held in New York City at 1:50 p.m. EST.
These presentations will be webcast live and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Contact: Jennifer McNealey [email protected] 650-870-1071
